Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety, Efficacy, and Pharmacokinetics of CD19-targeted CAR-T Cell Injection for the Treatment of Autoimmune Diseases Mediated by Autoantibodies.

NCT06548620 is registered in ClinicalTrials.gov with Nanjing Bioheng Biotech Co., Ltd. as lead sponsor.

NCT NCT06548620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06548620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety, Efficacy, and Pharmacokinetics of CD19-targeted CAR-T Cell Injection for the Treatment of Autoimmune Diseases Mediated by Autoantibodies.
Lead sponsor
Nanjing Bioheng Biotech Co., Ltd.
Phase
Phase 1
Overall status
Withdrawn
Start date
August 31, 2024
Completion date
August 31, 2027
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, iim, mg, ms, nmo spectrum disorder, sclerosis, sle, ss